The natural ingredients company signed the deal, of which financial details have not been disclosed, with an Estée Lauder subsidiary relating to the development and commercialization of its proprietary natural ingredients.
Harvey Gedeon, executive vice president Global Research, Development and Product Innovation for Estée Lauder stated that the agreement symbolizes a strong synergy of the two companies, and on which the beauty brand has already acted upon.
“The combination of Unigen’s commitment to developing highly effective cosmetic ingredients with the Estée Lauder Companies’ outstanding product development expertise will result in even better performing products for our consumers,” he said.
“We are pleased to have the exclusive rights to important Unigen discoveries – the first of which is now being used in Clinique’s exciting new products. We look forward to working with Unigen’s scientists to bring additional benefits to our other products and brands.”
For Estée Lauder the agreement formalizes an important and commercially successful collaboration with one of the leading experts in discovery and development of proprietary natural ingredients for the cosmetics and personal care industries.
“The greatest reward for scientists is to see their discovery successfully commercialized and provide meaningful benefits. We are delighted that a company with the Estée Lauder Companies’ stature and global reach has committed to showcase our scientists’ discoveries,” said Ed Cannon, Ph.D., Unigen’s CEO.
“Unigen shares a commitment to people and planet, and we are excited by the new product potential of combining the Estée Lauder Companies’ skin biology expertise with Unigen’s natural products chemistry and biology expertise.”
The first combination will take place concerning Clinique’s Even Better Clinical Dark Spot Corrector and its Derma White Clinical Brightening Essence, both skin care products aimed at improving the appearance of skin and limiting the appearance of pigmentation.